These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 9449031)

  • 1. Potential applications of GH secretagogs in the evaluation and treatment of the age-related decline in growth hormone secretion.
    Merriam GR; Buchner DM; Prinz PN; Schwartz RS; Vitiello MV
    Endocrine; 1997 Aug; 7(1):49-52. PubMed ID: 9449031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulation of the growth hormone-insulin-like growth factor I axis in developing and adult monkeys is affected by estradiol replacement and supplementation with insulin-like growth factor I.
    Wilson ME
    J Clin Endocrinol Metab; 1998 Jun; 83(6):2018-28. PubMed ID: 9626134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The somatotropic axis in critical illness: effect of continuous growth hormone (GH)-releasing hormone and GH-releasing peptide-2 infusion.
    Van den Berghe G; de Zegher F; Veldhuis JD; Wouters P; Awouters M; Verbruggen W; Schetz M; Verwaest C; Lauwers P; Bouillon R; Bowers CY
    J Clin Endocrinol Metab; 1997 Feb; 82(2):590-9. PubMed ID: 9024260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant human GHRH(1-44)NH2: clinical utility and therapeutic development program.
    Ehlers MR
    Endocrine; 2001 Feb; 14(1):137-41. PubMed ID: 11322496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained elevation of pulsatile growth hormone (GH) secretion and insulin-like growth factor I (IGF-I), IGF-binding protein-3 (IGFBP-3), and IGFBP-5 concentrations during 30-day continuous subcutaneous infusion of GH-releasing peptide-2 in older men and women.
    Bowers CY; Granda R; Mohan S; Kuipers J; Baylink D; Veldhuis JD
    J Clin Endocrinol Metab; 2004 May; 89(5):2290-300. PubMed ID: 15126555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Growth hormone-releasing hormone and growth hormone-releasing peptide as therapeutic agents to enhance growth hormone secretion in disease and aging.
    Thorner MO; Chapman IM; Gaylinn BD; Pezzoli SS; Hartman ML
    Recent Prog Horm Res; 1997; 52():215-44; discussion 244-6. PubMed ID: 9238854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Growth hormone/insulin-like growth factor-1 response to acute and chronic growth hormone-releasing peptide-2, growth hormone-releasing hormone 1-44NH2 and in combination in older men and women with decreased growth hormone secretion.
    Bowers CY; Granda-Ayala R
    Endocrine; 2001 Feb; 14(1):79-86. PubMed ID: 11322505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women.
    Khorram O; Laughlin GA; Yen SS
    J Clin Endocrinol Metab; 1997 May; 82(5):1472-9. PubMed ID: 9141536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The chronic oral administration of arginine aspartate decreases secretion of IGF-1 and IGFBP-3 in healthy volunteers.
    Blazejewski S; Georges A; Forest K; Corcuff JB; Abouelfath A; Girodet PO; Kamagate M; Jacquet A; Pillet O; Bordenave L; Moore N
    Fundam Clin Pharmacol; 2009 Jun; 23(3):339-44. PubMed ID: 19527301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of oral versus transdermal estrogen on the growth hormone/insulin-like growth factor I axis in younger and older postmenopausal women: a clinical research center study.
    Bellantoni MF; Vittone J; Campfield AT; Bass KM; Harman SM; Blackman MR
    J Clin Endocrinol Metab; 1996 Aug; 81(8):2848-53. PubMed ID: 8768841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth hormone-releasing hormone and growth hormone secretagogues in normal aging.
    Merriam GR; Schwartz RS; Vitiello MV
    Endocrine; 2003 Oct; 22(1):41-8. PubMed ID: 14610297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nocturnal augmentation of growth hormone (GH) secretion is preserved during repetitive bolus administration of GH-releasing hormone: potential involvement of endogenous somatostatin--a clinical research center study.
    Jaffe CA; Turgeon DK; Friberg RD; Watkins PB; Barkan AL
    J Clin Endocrinol Metab; 1995 Nov; 80(11):3321-6. PubMed ID: 7593445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leptin levels in protracted critical illness: effects of growth hormone-secretagogues and thyrotropin-releasing hormone.
    Van den Berghe G; Wouters P; Carlsson L; Baxter RC; Bouillon R; Bowers CY
    J Clin Endocrinol Metab; 1998 Sep; 83(9):3062-70. PubMed ID: 9745404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth hormone secretagogues in critical illness.
    Van den Berghe G
    Horm Res; 1999; 51 Suppl 3():21-8. PubMed ID: 10592440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insights into a role of GH secretagogues in reversing the age-related decline in the GH/IGF-I axis.
    Frutos MG; Cacicedo L; Fernández C; Vicent D; Velasco B; Zapatero H; Sánchez-Franco F
    Am J Physiol Endocrinol Metab; 2007 Nov; 293(5):E1140-52. PubMed ID: 17684105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The growth hormone (GH)-releasing hormone (GHRH)-GH-somatomedin axis: evidence for rapid inhibition of GHRH-elicited GH release by insulin-like growth factors I and II.
    Ceda GP; Davis RG; Rosenfeld RG; Hoffman AR
    Endocrinology; 1987 Apr; 120(4):1658-62. PubMed ID: 3104015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of oral administration of ibutamoren mesylate, a nonpeptide growth hormone secretagogue, on the growth hormone-insulin-like growth factor I axis in growth hormone-deficient children.
    Codner E; Cassorla F; Tiulpakov AN; Mericq MV; Avila A; Pescovitz OH; Svensson J; Cerchio K; Krupa D; Gertz BJ; Murphy G
    Clin Pharmacol Ther; 2001 Jul; 70(1):91-8. PubMed ID: 11452249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.
    Ionescu M; Frohman LA
    J Clin Endocrinol Metab; 2006 Dec; 91(12):4792-7. PubMed ID: 17018654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of alcohol and liver cirrhosis on the GH-IGF-I axis.
    Santolaria F; González-González G; González-Reimers E; Martínez-Riera A; Milena A; Rodgíguez-Moreno F; González-García C
    Alcohol Alcohol; 1995 Nov; 30(6):703-8. PubMed ID: 8679009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Continuous subcutaneous infusions of growth hormone (GH) releasing hormone 1-44 for 14 days increase GH and insulin-like growth factor-I levels in old men.
    Corpas E; Harman SM; Piñeyro MA; Roberson R; Blackman MR
    J Clin Endocrinol Metab; 1993 Jan; 76(1):134-8. PubMed ID: 8421077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.